Back to results
US 8,785,635 B2Granted
Cyclopamine analogs
AssigneeInfinity Pharmaceuticals, Inc.
InventorsBrian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Martin Tremblay
Life of this patent
Estimating the term…
Abstract
The invention provides novel derivatives of cyclopamine having the following formula:
Claims38
A compound represented by the following structure:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- R1 is H, alkyl, —OR, amino, sulfonamido, sulfamido, —OC(O)R5, —N(R5)C(O)R5 or a sugar;
- R2 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, nitrile, or 3-7 membered heterocycloalkyl that includes from 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or R1 and R2 taken together form ═O, ═S, ═N(OR), ═N(R), ═N(NR2), or ═C(R)2;
- R3 is H, alkyl, alkenyl, or alkynyl;
- R4 is H;
- alkyl;
- alkenyl;
- alkynyl;
- aryl;
- cycloalkyl;
- 3-7 membered heterocycloalkyl that includes from 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- aralkyl;
- 5-6 membered heteroaryl that includes from 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- heteroaralkyl, wherein the heteroaryl portion is a 5-6 membered heteroaryl that includes from 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- haloalkyl;
- —OR;
- —C(O)R5;
- —CO2R5;
- —SO2R5;
- —C(O)N(R5)(R5);
- —[C(R)2]q—R5;
- —[(W)—N(R)C(O)]qR5;
- —[(W)—C(O)]qR5;
- —[(W)—C(O)O]qR5;
- —[(W)—OC(O)]qR5;
- —[(W)—SO2]qR5;
- —[(W)—N(R5)SO2]qR5;
- —[(W)—C(O)N(R5)]qR5;
- —[(W)—O]qR5;
- —[(W)—N(R)]qR5;
- —W—NR3+X−;
- or —[(W)—S]qR5;
- wherein each W is, independently, a diradical;
- each q is independently for each occurrence 1, 2, 3, 4, 5, or 6;
- X− is a halide;
- each R5 is, independently, H;
- alkyl;
- alkenyl;
- alkynyl;
- aryl;
- cycloalkyl;
- 3-7 membered heterocycloalkyl that includes from 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- aralkyl;
- 5-6 membered heteroaryl that includes from 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- heteroaralkyl, wherein the heteroaryl portion is a 5-6 membered heteroaryl that includes from 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- or —[C(R)2]p—R6;
- wherein p is 0-6;
- or any two occurrences of R5 on the same substituent can be taken together to form a 4-8 membered optionally substituted ring which contains 0-3 heteroatoms selected from N, O, S, and P;
- each R6 is independently hydroxyl, —N(R)COR, —N(R)C(O)OR, —N(R)SO2(R), —C(O)N(R)2, —OC(O)N(R)(R), —SO2N(R)(R), —N(R)(R), —COOR, —C(O)N(OH)(R), —OS(O)2OR, —S(O)2OR, —OP(O)(OR)(OR), —NP(O)(OR)(OR), or —P(O)(OR)(OR);
- each R is independently H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl or aralkyl;
- provided that when R2, R3, and R4 are H;
- R1 is not hydroxyl or a sugar;
- further
- provided that when R4 is hydroxyl, then R1 is not a sugar or hydroxyl;
- further
- provided that when R4 is hydroxyl, then R1 and R2 together are not C═O.
55 more elements
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A composition comprising a mixture of
- or a pharmaceutically acceptable salt thereof.
An isolated compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.